Interferon in the treatment of chronic hepatitis C: A drug caught between past and future

Expert Opinion on Biological Therapy

Volumn 11, Issue 3, 2011, Pages 301-313

  Vezali, Elena ^a,b   Aghemo, Alessio ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

albumin interferon; consensus interferon; directly acting antivirals; hepatitis C; interferon alfa; interferon lambda; interferon omega

Indexed keywords

ALBINTERFERON ALPHA2B; BETA INTERFERON; CONSENSUS INTERFERON; FUNGUS VACCINE; GAMMA INTERFERON; GI 5005; INTERFERON; INTERLEUKIN 29; OMEGA INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; SILIBININ; SILYMARIN; UNCLASSIFIED DRUG; VIRUS RNA;

AFRICAN AMERICAN; ANEMIA; ANXIETY DISORDER; CAUCASIAN; DEPRESSION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEPATITIS C; HUMAN; INSOMNIA; MYALGIA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; REVIEW; RIGOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 79851470805     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.552906     Document Type: Review

References (103)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81
2. Kim WR The burden of hepatitis C in the United States. Hepatology 2002;36(Suppl):S30-4 (Pubitemid 35253461)
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007;14:107-15 (Pubitemid 46146705)
4. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73 (Pubitemid 41401136)
5. Liang TJ, Rehermann B, SeeffLB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305 (Pubitemid 30106261)
6. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72 (Pubitemid 27078833)
7. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98 (Pubitemid 40968202)
8. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009;104:2439-48
9. Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010;53:36-42
10. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8 (Pubitemid 17055392)
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
12. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
13. Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon CytokineRes 1999;19:1069-98 (Pubitemid 29502774)
14. Bach EA, Aguet M, Schreiber RD. The IFNgamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91 (Pubitemid 27169292)
15. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77 (Pubitemid 36109115)
16. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 2003;4:63-8 (Pubitemid 36104710)
17. Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906 (Pubitemid 46489554)
18. Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009;35:82-7
19. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-87 (Pubitemid 37328725)
20. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-102
21. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83
22. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996;23:909-16 (Pubitemid 26112009)
23. Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375-83
24. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83
25. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26(3 Suppl 1):83S-88S
26. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-332
27. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92 (Pubitemid 28543496)
28. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51 (Pubitemid 32738660)
29. Veronese FM, Mero A. The impact of Pegylation on biological therapies. BioDrugs 2008;22:315-29
30. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
31. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004;20:825-30 (Pubitemid 39424889)
32. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65 (Pubitemid 32913521)
33. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
34. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
35. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15
36. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138(1):116-22
37. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51:1176-84
38. Rumi MG. Pegylated interferon alphaalpha2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority. J Hepatol 2009;51:1097-9
39. Crax̀ A. PEG IFN alfa-2a vs. alfa-2b: and the winner is..? J Hepatol 2010;52:133-5
40. Aghemo A, Colombo M. Peginterferon alfa-2B versus peginterferon alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal. Gastroenterology 2010;138:386-9
41. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131(4):1040-8 (Pubitemid 44515099)
42. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475-81 (Pubitemid 351798988)
43. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47 (Pubitemid 47171919)
44. Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat 2010;17:459-68
45. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
46. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
47. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
48. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9
49. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-14
50. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-7
51. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51(2):388-97
52. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33 (Pubitemid 41111423)
53. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17 (Pubitemid 41007847)
54. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007;46:1732-40
55. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52 (Pubitemid 37052151)
56. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94
57. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97
58. Mac Nicholas R, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV-the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 2010;31:929-37
59. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-8 (Pubitemid 43839429)
60. Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006;24:1067-77 (Pubitemid 44386532)
61. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64 (Pubitemid 43049856)
62. Balan V, Nelson DR, Sulkowski MS, et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006;11:35-45
63. Zeuzem S, Sulkowski MS, Lawitz EJ, et al.; ACHIEVE-1 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010;139:1257-66
64. Nelson DR, Benhamou Y, Chuang WL, et al.; ACHIEVE-2/3 Study Team. Albinterferon alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology. 2010;139:1267-76
65. Human Genome Sciences announces preliminary feedback from FDA on Zalbin BLA for chronic hepatitis C [press release]. Rockville, MD: Human Genome Sciences, Inc.; 14 June 2010. Available from: http://www.hgsi.com/latest/human- genome-sciences-announces-preliminary-feedback-from-fda-on-zalbin-bla-for- chronic-hepati-7. html [Last accessed 6 January 2011]
66. Human Genome Sciences announces withdrawal of European Marketing Authorization Application for Jouferon® Zalbin™ for the treatment of chronic hepatitis C [press release]. Rockville, MD: Human Genome Sciences, Inc.; April 2010. Available from: http://www.hgsi.com/latest/human-genome-sciences- announces-withdrawal-of-european-marketing-authorization-application-for- joulferon-zalbin-for-the-treatment-of-chronic-hepati-7.html [Last accessed 6 January 2011]
67. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 2003;4:63-8 (Pubitemid 36104710)
68. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and a; inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-98 (Pubitemid 44958521)
69. Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906 (Pubitemid 46489554)
70. Miller DM, Klucher KM, Freeman JA, et al. Interferon lambda as a potential new therapeutic for hepatitis C. Ann NY Acad Sci 2009;1182:80-7
71. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822-32
72. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
73. Rauch A, Kutalik Z, Descombes P, et al.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45
74. Adolf GR Human interferon omega-a review. Mult Scler 1995;1(Suppl 1):S44-7
75. Okuse C, Rinaudo JA, Farrar K, et al. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res 2005;65:23-34 (Pubitemid 40094771)
76. Buckwold VE, Wei J, Huang Z, et al. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res 2007;73:118-25 (Pubitemid 46138065)
77. Novozhenov V, Zakharova N, Vinogradova E, et al. Phase II study of omega interferon alone or in combination with tribavirin in subjects with chronic hepatitis C genotype-1 infection. J Hepatol 2007;46(Suppl 1):S8
78. Rohloff CM, Alessi TR, Yang B, et al. DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008;2:461-7
79. Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment. Bethesda, MD, clinicaltrials.gov, 2007, Available from: http://www.clinicaltrials.gov/ct2/show/NCT00519792?term= Hepatitis& recr=Open&rank=117. [Last accessed 6 January 2011]
80. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996;16:489-99 (Pubitemid 26306949)
81. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009;49:1838-46
82. Blatt LM, Cheung E, Radhakrisma R, et al. A phase 1, single-blind, dose-escalating study of the safety and pharmacokinetics of a single injection of pegylated interferon alfacon-1 in healthy volunteers [abstract]. Gastroenterology 2005;128:S713
83. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98 (Pubitemid 46695724)
84. Zhou Y, Muh U, Bartel D, et al. In vitro characterizarion ofTelaprevir (VX-950) NS3 Protease variants [abstract 89]. Hepatology 2006;44(4 Suppl 1):S221A
85. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006;69:129-41 (Pubitemid 43247333)
86. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002 (Pubitemid 44498690)
87. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77 (Pubitemid 46677938)
88. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-18
89. Hezode C, Forestier N, Dusheiko G, et al.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
90. McHutchison JG, Manns MP, Muir AJ, et al.; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
91. Kwo PY, Lawitz EJ, McCone J, et al.; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16
92. Forns X, Marcellin P, Ferenci P, et al. On-treatment response-guided therapy with Telaprevir q8h or q12h combined with Peginterferon alfa-2a or peginterferon alfa-2b and Ribavirin in treatment-naive genotype 1 hepatitis C (Study C208) [abstract 56]. J Hepatol 2010;52(1 Suppl 1):S26
93. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
94. Zeuzem S, Asselah T, Angus PW, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. AASLD 2010 Annual Meeting. Hepatology 2010;52(4 Suppl 1): abstract LB-7
95. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010;52:421-9
96. Ferenci P, Brunner H, Laferl H, et al.; Austrian Hepatitis Study Group. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008;47:1816-23 (Pubitemid 351945549)
97. Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009;13:403-17
98. Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN alpha2a in Chronic Hepatitis C Genotype 2 and 3 naive Patients. Bethesda, MD, clinicaltrials.gov, 2010. Available from: http://clinicaltrials. gov/show/NCT01215643. [Last accessed 6 January 2011]
99. Silybin drug information. U.S. National Library of Medicine, Bethesda, MD, 2011. Available from: http://druginfo.nlm.nih.gov/drugportal/ProxyServlet? mergeData=true&objectHandle=DBMaint&APPLICATION-NAME= drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen. jsp&TXTSUPERLISTID=0022888706&QV1=SILYBIN [Last accessed 5 January 2011]
100. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008;135:1561-7
101. Ferenci P, Munda P. Intravenous Silibinin in combination with Peg-interferon and Ribavirin in nonresponders (NRSily). Clinical Trial NCT00684268. Bethesda, MD, clinicaltrials.gov, 2008. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00684268?term=NCT00684268& rank=1 [Last accessed 6 January 2011]
102. Scherze T, Staube ER, Maieron A, et al. Undetectable HCV RNA after Silibinin iv treatment is associated with high on treatment response rates in HCV nullresponders. AASLD 2010 Annual Meeting [abstract 835]. Hepatology 2010;52(4 Suppl l):723A
103. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009;11:456-62